393 related articles for article (PubMed ID: 23456737)
21. Targeting a cell state common to triple-negative breast cancers.
Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
[TBL] [Abstract][Full Text] [Related]
22. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
Gordon V; Banerji S
Clin Cancer Res; 2013 Jul; 19(14):3738-44. PubMed ID: 23748695
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets.
Gautam P; Jaiswal A; Aittokallio T; Al-Ali H; Wennerberg K
Cell Chem Biol; 2019 Jul; 26(7):970-979.e4. PubMed ID: 31056464
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
26. Advances in small-molecule drug discovery for triple-negative breast cancer.
Fosu-Mensah N; Peris MS; Weeks HP; Cai J; Westwell AD
Future Med Chem; 2015; 7(15):2019-39. PubMed ID: 26495746
[TBL] [Abstract][Full Text] [Related]
27. A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.
Matossian MD; Burks HE; Elliott S; Hoang VT; Zuercher WJ; Wells C; Drewry DH; Kapadia N; Chang T; Yan T; Windsor GO; Nguyen K; Fang F; Nephew KP; Buechlein A; Rusch DB; Sabol RA; Ucar DA; Zabaleta J; Miele L; Bunnell BA; Collins-Burow BM; Burow ME
Anticancer Drugs; 2020 Sep; 31(8):759-775. PubMed ID: 32796402
[TBL] [Abstract][Full Text] [Related]
28. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity.
Roberts LS; Yan P; Bateman LA; Nomura DK
ACS Chem Biol; 2017 Apr; 12(4):1133-1140. PubMed ID: 28248089
[TBL] [Abstract][Full Text] [Related]
29. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
[TBL] [Abstract][Full Text] [Related]
31. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
[TBL] [Abstract][Full Text] [Related]
32. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
[TBL] [Abstract][Full Text] [Related]
34. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
[TBL] [Abstract][Full Text] [Related]
35. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
36. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
37. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule PB; Crown J; O'Donovan N; Duffy MJ
Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
[TBL] [Abstract][Full Text] [Related]
38. The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.
Makvandi M; Tilahun ED; Lieberman BP; Anderson RC; Zeng C; Xu K; Hou C; McDonald ES; Pryma DA; Mach RH
Biochem Biophys Res Commun; 2015 Nov; 467(4):1070-5. PubMed ID: 26453012
[TBL] [Abstract][Full Text] [Related]
39. A Phenotypic Cell-Binding Screen Identifies a Novel Compound Targeting Triple-Negative Breast Cancer.
Chen L; Long C; Youn J; Lee J
ACS Comb Sci; 2018 Jun; 20(6):330-334. PubMed ID: 29718663
[TBL] [Abstract][Full Text] [Related]
40. Triple negative breast cancer: a multi-omics network discovery strategy for candidate targets and driving pathways.
Karagoz K; Sinha R; Arga KY
OMICS; 2015 Feb; 19(2):115-30. PubMed ID: 25611337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
